Logo image of VTRS

VIATRIS INC (VTRS) Stock Price, Forecast & Analysis

USA - NASDAQ:VTRS - US92556V1061 - Common Stock

10.36 USD
0 (0%)
Last: 10/31/2025, 8:19:01 PM
10.34 USD
-0.02 (-0.19%)
After Hours: 10/31/2025, 8:19:01 PM

VTRS Key Statistics, Chart & Performance

Key Statistics
Market Cap12.08B
Revenue(TTM)14.12B
Net Income(TTM)-3468300000
Shares1.17B
Float1.16B
52 Week High13.55
52 Week Low6.85
Yearly Dividend0.48
Dividend Yield4.63%
EPS(TTM)2.41
PE4.3
Fwd PE4.15
Earnings (Next)11-06 2025-11-06/bmo
IPO1973-02-01
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


VTRS short term performance overview.The bars show the price performance of VTRS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 5 10 15

VTRS long term performance overview.The bars show the price performance of VTRS in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 5 -5 10 -10 15

The current stock price of VTRS is 10.36 USD. In the past month the price increased by 1.67%. In the past year, price decreased by -10.84%.

VIATRIS INC / VTRS Daily stock chart

VTRS Latest News, Press Relases and Analysis

VTRS Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 39.24 816.66B
JNJ JOHNSON & JOHNSON 18.2 454.86B
AZN ASTRAZENECA PLC-SPONS ADR 18.56 255.48B
NVS NOVARTIS AG-SPONSORED ADR 13.83 239.64B
NVO NOVO-NORDISK A/S-SPONS ADR 12.81 219.77B
MRK MERCK & CO. INC. 9.87 214.76B
PFE PFIZER INC 7.27 140.15B
SNY SANOFI-ADR 11.52 123.27B
GSK GSK PLC-SPON ADR 7.73 94.25B
BMY BRISTOL-MYERS SQUIBB CO 7.02 93.77B
ZTS ZOETIS INC 23.17 63.86B
TAK TAKEDA PHARMACEUTIC-SP ADR 48 42.45B

About VTRS

Company Profile

VTRS logo image Viatris, Inc. is a global healthcare company, which engages in the provision of healthcare and pharmaceutical products. The company is headquartered in Canonsburg, Pennsylvania and currently employs 32,000 full-time employees. The firm's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. The company produces oral solid doses, injectables, and products with complex dosage forms.

Company Info

VIATRIS INC

1000 Mylan Boulevard

Canonsburg PENNSYLVANIA 15317 US

CEO: Michael Goettler

Employees: 32000

VTRS Company Website

VTRS Investor Relations

Phone: 17245141465

VIATRIS INC / VTRS FAQ

What does VIATRIS INC do?

Viatris, Inc. is a global healthcare company, which engages in the provision of healthcare and pharmaceutical products. The company is headquartered in Canonsburg, Pennsylvania and currently employs 32,000 full-time employees. The firm's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. The company produces oral solid doses, injectables, and products with complex dosage forms.


Can you provide the latest stock price for VIATRIS INC?

The current stock price of VTRS is 10.36 USD.


Does VTRS stock pay dividends?

VIATRIS INC (VTRS) has a dividend yield of 4.63%. The yearly dividend amount is currently 0.48.


What is the ChartMill technical and fundamental rating of VTRS stock?

VTRS has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 4 out of 10.


When is the next dividend date for VIATRIS INC (VTRS)?

The next ex-dividend date for VIATRIS INC (VTRS) is August 22, 2025.


Should I buy VTRS stock?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on VTRS.


Can you provide the growth outlook for VIATRIS INC?

The Revenue of VIATRIS INC (VTRS) is expected to decline by -6.08% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


VTRS Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to VTRS. When comparing the yearly performance of all stocks, VTRS turns out to be only a medium performer in the overall market: it outperformed 49.04% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

VTRS Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to VTRS. While VTRS is still in line with the averages on profitability rating, there are concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

VTRS Financial Highlights

Over the last trailing twelve months VTRS reported a non-GAAP Earnings per Share(EPS) of 2.41. The EPS decreased by -13% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -9.03%
ROE -22.27%
Debt/Equity 0.82
Chartmill High Growth Momentum
EPS Q2Q%-10.14%
Sales Q2Q%-5.65%
EPS 1Y (TTM)-13%
Revenue 1Y (TTM)-7.37%

VTRS Forecast & Estimates

14 analysts have analysed VTRS and the average price target is 11.98 USD. This implies a price increase of 15.63% is expected in the next year compared to the current price of 10.36.

For the next year, analysts expect an EPS growth of -11.97% and a revenue growth -6.08% for VTRS


Analysts
Analysts54.29
Price Target11.98 (15.64%)
EPS Next Y-11.97%
Revenue Next Year-6.08%

VTRS Ownership

Ownership
Inst Owners85.59%
Ins Owners0.25%
Short Float %2.48%
Short Ratio3.27